Embryonic stem cells (ESCs) are characterized by their ability to self-renew and to differentiate into all cell types of a given organism. Understanding the molecular mechanisms that govern the ESC state is of great interest not only for basic research-for instance, ESCs represent a perfect system to study cellular differentiation in vitro-but also for their potential implications in human health-these mechanisms are likewise involved in cancer progression and could be exploited in regenerative medicine. In this minireview, we focus on the latest insight into the molecular mechanisms mediated by the pluripotency factors as well as their roles during differentiation. We also discuss recent advances on understanding the function of the epigenetic regulators, Polycomb and MLL complexes, in ESC biology.
Introduction
Within two days after fertilization, a mouse oocyte has undergone a series of cellular divisions and has developed into the morula embryo. The totipotent cells within the morula then divide and further specialize to form the hollow blastocyst sphere. The outer layer of the blastocyst contains the trophectoderm cells, while the inner cell mass (ICM) contain the pluripotent stem cells (ESCs) that will give rise in the developing embryo to all cell types of the three germ layers-ectoderm, mesoderm, and endoderm. Mouse ESCs were firstly isolated by Evans and Kaufman in 1981 (1) and have since been extensively studied.
Under proper cell culture conditions, ESCs can divide and self-renew indefinitely, yet under differentiation stimuli, ESCs can also differentiate into virtually all cell types of the organism.
Which molecular mechanisms control the decision of ESCs to self-renew or to differentiation? During the last decades, several transcription factors have been identified to be essential for ESC pluripotency. These transcription factors regulate pluripotency by a so-called "pluripotency network" that regulates their own expression and co-regulates the expression of other key transcription factors through multiple mechanisms. Interestingly, pluripotency is controlled at the transcriptional levels of genes through specific signaling pathways and epigenetic factors.
Epigenetics is the study of heritable changes in gene expression that are not caused by changes at the DNA sequence. The Polycomb and MLL (myeloidlineage leukemia) complexes are two of the best characterized epigenetic machineries implicated in ESC pluripotency and differentiation. Although pluripotency factors do not physically interact with Polycomb and MLL complexes, they co-regulate lineage-specific genes important for ESC differentiation.
In this review, we discuss the most recent advances in understanding mouse ESC pluripotency and differentiation, paying particular attention to Oct4, Nanog, and Sox2, as well as to factors involved in the exit of pluripotency. Finally, we discuss the function and the molecular mechanisms of the Polycomb and MLL complexes in mouse ESC pluripotency.
Master regulators of ESC identity: the Oct4, Sox2, and Nanog triumvirate.
Pluripotency and self-renewal are considered to be unwavering features of ESCs, yet the ICM of the developing embryo has a half-life of only about a day. The pluripotent state is therefore an ephemeral biological state that is tightly regulated by transcription factors, signaling pathways, and epigenetic machineries. Several transcription factors have been shown to be indispensable in regulating the pluripotent state of ESC in vivo and in vitro. Among these factors, we will discuss the biological function of the triumvirate of Oct4, Sox2, and Nanog.
Oct4, Sox2, and Nanog expression and functions.
The transcription factor Oct4 (octamer-binding transcription factor 4) was one of the first factors identified as a master regulator of ESC pluripotency (2) (3) (4) . It is highly expressed in the blastocyst ICM (5) , and its expression rapidly decreases during embryo development; indeed, Oct4 is widely used as a reporter marker to assess for differentiation (6) . Accordingly, Oct4 null embryos fail to form a pluripotent ICM and do not develop beyond the blastocyst stage (5) . Oct4 expression is tightly regulated, and reduction of only 50% causes spontaneous differentiation of ESCs towards the trophoectoderm (TE) lineage (7) .
Another master regulator of ESC pluripotency is Sox2 (Sry-box containing gene 2) (8) . Similar to Oct4, Sox2 is also highly expressed in the ICM, where it is essential to retain the maximum pluripotency capacity of the ESCs (9) . Changes of Sox2 expression in ESCs also trigger differentiation: overexpression induces differentiation towards neuroectodermal cells (10) , whereas Sox2 deletion results in TE differentiation. Furthermore, targeted disruption of Sox2 in vivo results in peri-implantation lethality due to a strong impairment of the ICM (8).
Importantly, Sox2 expression is not restricted to ESCs: in adult mice, Sox2 expression is maintained in many adult stem/progenitor stem cells (8, 11) . Nanog is another transcription factor involved in the ESC pluripotency network (12) . Nanog is highly expressed not only in the ICM but also in the epiblast cells of the embryo (13) . Similar to Oct4-and Sox2 null mutants, Nanog-null embryos fail to develop. However, in contrast to those from Oct4-and Sox2 null mutants, ESCs from Nanog mutant embryos can be derived and maintained in culture, indicating that Nanog is dispensable for ESC self-renewal (14) .
Oct4, Sox2, and Nanog are implicated in a regulatory network.
Oct4, Sox, and Nanog (shorted to O.S.N) do not work independently but rather are involved in an intricate regulatory circuitry, in which other transcription factors are also implicated (15) (16) (17) (18) (19) MTLs, 43.4% of which were co-occupied by Oct4, Sox2, and Nanog, indicating a functional cooperation in gene regulation (17) . Moreover, O.S.N regulate their expression positively by binding to their own promoters, co-occupy and activate expression of other genes essential for maintaining ESC pluripotency, and cooperate to repress lineage-specific transcription factors, the silencing of which is essential to prevent exit from pluripotency and spontaneous differentiation.
The ability of O.S.N to positively or negatively regulate gene expression relies on their ability to interact with specific transcription factors and epigenetic machineries, and great effort have been made recently to characterize the interactome of these three factors (6, (20) (21) (22) . Despite a few differences between these reports, all of them converge in identifying numerous associated proteins, including nucleosome-remodeling complexes (such as SWI/SNF [23] and NuRD [21] ), histone methyltransferases (i.e. SetDB1 [24] and Wdr5 [24] ), enhancerassociated factors (i.e. Mediator [25]), and pluripotency factors (20, 21, 26) . For instance, it has been shown that Oct4 and Nanog associate with proteins of the NuRD complex, Mta1/2 and HDAC1/2, to compose a unique complex (termed NODE) that has a deacetylation activity comparable to that of the NuRD complex, connecting Oct4 and Nanog to repressor functions (21 Interestingly, Oct4 and Sox2 have been related to a group of proteins with apparently divergent functions from the heterotrimeric XPC-nucleotide excission repair (NER) complex, implicated in DNA damage repair. Fong and colleagues reported that the XPC complex functions as a co-activator required to enhance Nanog transcriptional activity. Combined loss-of-function studies of these proteins compromised mESC pluripotency as well as reprogramming efficiency using mouse embryonic fibroblasts (MEF) (27).
Pluripotency factors in cell fate commitment.
In addition to their role in maintaining ESC pluripotency and self-renewal, O.S.N.
have also been proposed to be involved in early cell fate decisions (16, 28) . Several studies have shown that Oct4 has explicit lineage-specifying functions (16, (29) (30) (31) (32) . Initial reports revealed that ESCs expressing higher Oct4 levels induce differentiation towards the mesoendoderm lineage (33). Indeed, Thompson and colleagues showed a specific cross-regulation between Oct4 and Sox2 in early stages of germ layer differentiation (16) . In ESCs, expression of these two factors decreases once the cells enter the differentiation program; however, Oct4 and Sox2 are required in these cells to specify the following mesoendoderm (ME) and neuroectoderm lineages (NE), respectively. In ME cells, Oct4 occupies the enhancer regulatory region of Sox2, inhibiting its expression.
In contrast, Oct4 is not expressed in NE cells, so that Sox2 can bind to its enhancer region to activate its own transcription. Thus, when they are coexpressed, Oct4 and Sox2 repress differentiation, but when they are asymmetrically expressed, they can activate specific differentiation programs while inhibiting others (16) .
Oct4 is also involved in the first cell-fate decision in the developing embryo that occurs at the 16- In the TE cells, the chromatin remodeling protein Brg1 cooperates with Cdx2 to ensure Oct4 repression (34), while in the ICM, the H3K9 histone methyltransferase Setdb1 interacts with Oct4 to silence Cdx2 expression and other TE-associated genes (24) .
Nanog is also involved in regulating cell fate commitment at early stages of development. Soon after the ICM and TE lineages have been specified, a second differentiation process results in the formation of two new layers of specialized cells: the primitive endoderm (PrE), which will form the extraembryonic endoderm tissues of the placenta, and the epiblast cells, which will give rise to the three germ layers of the embryo. Before implantation, Nanog and Gata6 are expressed in a mutually exclusive manner, which has been described as a "saltand-pepper" expression pattern, as they inhibit each other's expression (35).
Moreover, Nanog depletion in ESCs induces expression of PrE markers, suggesting that only repressing Nanog is sufficient to induce PrE differentiation, and that forcing expression of Gata6 causes Nanog downregulation, Betschinger and coworkers applied a large-scale siRNA screen to interrogate which factors are involved in the exit of pluripotency (42) . In this assay, cells that had been depleted for Flcn (follicullin) and Tsc2 (Tuberous Sclerosis 2) retained Oct4 expression and self-renewed when they were cultured in a permissive A similar experimental approach using haploid ESCs identified additional factors not previously connected to regulating ESC fate commitment: the zinc finger protein Zfp706 and the RNA-binding protein Pum1. A differentiation permissive medium was not enough to trigger differentiation after either Zfp706 or Pum1 had been depleted, and pluripotent colonies could be isolated 10 days after culturing the ESCs in this medium. Mechanistically, Zfp706 regulates Klf4, whose downregulation was known to be required to exit pluripotency (43) . Pum1 regulates mRNA stability by binding a highly conserved motif at the 3 UTR of several mRNAs. Potential Pum1 mRNA targets were identified using a bioinformatic prediction analysis and gene expression profiles after Pum1 depletion. Interestingly, mRNAs of pluripotency-related transcription factors, such as Klf4, Tfcp2l1, Tbx3, and Esrrb, were identified and validated as Pum1 targets. Thus, Pum1 contributes to the exit of self-renewal by directly regulating mRNA transcripts of several pluripotency factors (44) .
In the past few years, the long non-coding RNAs (lncRNAs) have emerged as key regulators of pluripotency as well as of the transition to the differentiated state.
Indeed, increasing evidence proves that these molecules are essential to ensure pluripotency (45, 46) . In this direction, Guttman and colleagues showed that the effects of a knockdown of large intergenic non-coding RNAs (lincRNA) in ESCs are comparable to those of knockdowns of well-known pluripotent factors (47) .
Better understood is the role of the lncRNA X-inactive specific transcript (Xist) in X-chromosome inactivation (XCI) during female ESC differentiation and its connection to the pluripotency network (48) . Future investigation will undoubtedly uncover novel functions of lncRNAs in ESCs.
These results suggest that disassembly of the pluripotency network takes place at multiple levels, which need to be concomitantly regulated to allow ESCs to determine their cell fates. The FGF signaling pathway additionally regulates lineage specification in the embryo. FGF4 is the main FGF factor expressed in the early stages of the embryo and in ESCs. This stem cell-specific expression pattern relies on the presence of a distant enhancer in the FGF4 promoter that is under the control of the pluripotency factors Oct4 and Sox2, which positively activate its transcription (57) . FGF4 plays a role not only in the ICM but also in TE lineage. Accordingly, trophoblast stem (TS) cells are highly enriched with the FGF4 receptor, FGF2r (58) . In fact, FGF4-and FGF2r-null embryos display a similar phenotype, as both are lethal at the peri-implantation stage (59, 60). Tanaka and coworkers were able to derive TS cells from blastocysts by treating the desegregated blastocysts with media containing FGF4. Therefore, the FGF4-mediated signal contributes to maintain trophoectoderm cells in proliferating and undifferentiated state (61) .
The function of FGF4 in ESCs has also been extensively studied. FGF4, through the activation of the Erk1/2 signaling cascade, acts as an auto-inductive stimuli for ESCs to exit self-renewal and to enter into the differentiation program. FGF4 null cells can be cultured and do not show any apparent defects, but they do not differentiate when they are cultured in media that induces neuronal or mesodermal differentiation, suggesting that FGF4 signaling, through the Erk1/2 pathway, may act as one of the primary signals to direct cell fate commitment (62) . Accordingly, Erk1/2 inhibitors have been extensively used to improve the efficiency of ESC derivation (63) .
ESCs maintained in serum and LIF are often morphologically heterogeneous and express pluripotency factors in a heterogeneous manner, indicating that the pluripotent state is unstable. Ying and colleagues defined specific culture conditions in which ESCs are more protected from differentiation stimuli, thereby resembling the transcriptional status of the ESCs in vivo (64) . This serum-free medium contains LIF and inhibitors of two kinases, PD0325901 (Mek kinase inhibitor) and CHIR99021 (GSK3 kinase inhibitor). This combination of molecules helps to maintain a naive ground state of the ESCs (64).
Cross-talk between pluripotency and epigenetic factors. (66, 71, 72) (Fig. 2) . The core PRC2 complex contains Suz12, Eed, and the histone methyltransferase enzymes Ezh1/2, which deposit di-and tri-methylation on lysine 27 of histone H3 (H3K27me2/3) (73). PRC1 complexes can be further divided into two main sub-complexes, namely, the canonical and non-canonical PRC1 (cPRC1 and ncPRC1, respectively). cPRC1 consists of Pcgf2/4, Polyhomeiotic (Phc1/2/3), the Cbx (Cbx2/4/6/7/8) proteins, and the E3-ligase subunit Ring1A/B, which monoubiquitinates histone H2A at lysine 119 (H2AK119ub). In contrast, ncPRC1 does not contain a Cbx protein but instead contains RYBP/YAF2, Pcgf1/3/5, and Ring1A/B (74-77) (Fig. 3) .
Polycomb-mediated gene repression mechanisms and target genes in ESCs.
In pluripotent ESCs, Polycomb complexes are recruited to lineage-specific gene promoters and are required to maintain gene repression (78) (79) (80) Recently, using a de novo targeting system in ESCs, the PRC2 complex was shown to be recruited to chromatin in a PRC1-dependent manner (83) . PRC1 complexes containing Pcgf1, Pcgf3, or Pcgf5 are first recruited to DNA, where they monoubiquitate H2AK119, which then drives PRC2 recruitment. Using the same targeting system, the authors also suggested that canonical PRC1 complexes fail to deposit H2AK119ub (83) .
The biological function of H2AK119ub is still poorly understood. Elegant studies by Koseki and colleagues indicate that the enzymatic activity of Ring1B in ESCs is necessary for gene repression and chromatin compaction (84) . Moreover, H2AK119ub serves as a recruitment platform for Zrf1 (Zuotin-related factor 1).
Upon differentiation of NT2 cells (human teratocarcinoma cells) and ESCs, Zrf1
binds to H2AK119ub and displaces the PRC1 complex from chromatin, resulting in upregulation of lineage genes with differentiation (85, 86) .
Molecular functions of the canonical and non-canonical PRC1 complexes in ESCs.
Recently, variations of PRC1 complexes have been identified in 293T cells and ESCs. In mouse ESCs, cPRC1 mainly contains Cbx7, Phc1, Mel18/Pcgf2, and Ring1B (87, 88) (Fig. 3) . Cbx7 depletion strongly reduces chromatin binding of Ring1B and Mel18. In turn, Cbx7 recruitment is fully dependent on H3K27me3, suggesting that the cPRC1 recruitment follows the hierarchical model in ESCs (87) . ncPRC1 has now been characterized in ESCs and shown to contain Kdm2b/Fbxl10 (H3K36me3 lysine demethylase), RYBP, Pcgf1/NsPC1, and Ring1B (77, 89) (Fig. 3) . Interestingly, Fbxl10 is a H3K36me3 demethylase and contains a CXXC domain (90) . Chromatin recruitment of this ncPRC1 complex depends on the CXXC domain of Kdm2b, which drives this ncPRC1 to CpG islands. Importantly, neither ncPRC1 recruitment nor its activity depends on Kdm2b histone demethylase activity (77, 89) .
Do these complexes have redundant functions in ESCs?
H2AK119ub global levels are not affected upon Cbx7 depletion and are only slightly reduced at target genes, yet depletion of either Kdm2b or Pcgf1 strongly reduces H2AK119ub. While Ring1B recruitment to chromatin is strongly reduced upon Cbx7 or Fbxl10 depletion, Fbxl10 is not required for Cbx7 recruitment (77, 87) , suggesting that cPRC1 is important for efficient Ring1B recruitment, while ncPRC1 is required for the enzymatic activity of Ring1B. RYBP appears to be also important for global and local H2AK119ub deposition (75-77, 87, 89) , and its depletion seems to induce Ring1B instability (75) . However, as this regulation might not be due to Ring1B degradation (74, 76, 77, 91) , the mechanism by which RYBP induces H2AK119ub deposition by Ring1B remains elusive.
Are the cPRC1 and ncPRC1 complexes recruited only to lineage-specific genes?
Or, in contrast, is there a certain degree of gene target selectivity by these PRC1 complexes? Lineage-specific genes are co-occupied by either both the cPRC1 and ncPRC1 or only the cPRC1 complex ( Fig. 4A and B) . These genes also contain high levels of PRC2 and are strongly repressed. Interestingly, a subset of ncPRC1-target genes (classified for the presence of RYBP and Ring1B, but without Cbx7), have low levels of H2AK119ub and PRC2 binding and are in turn less repressed; these genes are involved in germ cell fate and cellular metabolism (74) (Fig. 4B ).
Molecular functions of PRC2 complexes in ESCs.
The PRC2 complex architecture is not as heterogeneous as the PRC1 complex (Fig. 2 ), yet several co-factors have recently been identified to associate with PRC2 members in ESCs (92) . In the past years, the Jumanji protein Jarid2 was identified as the first protein to interact directly, via its interaction with Suz12, with the core PRC2 complex in ESCs. Jarid2 co-occupies a large set of PRC2 target genes, and its depletion greatly reduces PRC2 occupancy at promoters. Whether Jarid2 positively or negatively regulates PRC2 activity in ESCs is under debate (93) (94) (95) (96) (97) . Jarid2 contains a AT-rich interaction domain and was therefore postulated to be a recruiter to PRC2, yet to date it has not been demonstrated that Jarid2 can directly bind to DNA. Thus, it seems that Jarid2 is a component, but not a recruitment factor, of a specific PRC2 complex in ESCs.
In Drosophila, the Polycomb protein PCL interacts with Su(z) (97) In sum, four polypeptides, Jarid2, Phf19, Mtf2, and C17orf96, have been recently identified as new co-factors that sub-stoichiometrically associate with different PRC2 complexes in ESCs (Fig. 4A) . This raises numerous questions regarding the biological and molecular functions of these PRC2 sub-complexes: are they functionally redundant in gene regulation? Do they co-regulate the same target genes? Why does Mtf2 depletion enhance global PRC2 activity but reduce H3K27me3 and PRC2 binding at target genes? A comprehensive analysis of Jarid2, Phf19, Mtf2, and C17orf96 target genes and gene expression profile in ESCs depleted by these co-factors will shed light on the functional regulation of these PRC2 sub-complexes.
The exact mechanisms that drive PRC2 recruitment remain largely elusive.
Recently, it has been postulated that the PRC2 complex binds via Ezh2 to nascent RNAs (ezRNAs) at genes that lack H3K27me3, have intermediate or low levels of PRC2, and are transcriptionally active, suggesting that ezRNAs inhibits PRC2-activity (103) . While another report corroborated the interaction of ezRNAs with the PRC2 complex, it also suggested that a lack of H3K27me3 is not a prerequisite for the ezRNAs/PRC2 interaction (104).
Polycomb-mediated phenotypes in ESCs and mice.

PRC1 subunits.
Among all PRC1 members, Ring1B mutant mice display the most severe phenotype, and mice lacking Ring1B are embryonic lethal due to gastrulation defects. Mutant mice for other PRC1 subunits are viable (i.e., Ring1A, Mel18, Bmi1, Cbx2, and Phc1), yet they show homeotic transformations and other abnormalities of the axial skeleton (69) . Cbx7 mutant mice are viable, with increased body length, and develop lung and liver tumors (105) .
In ESCs, Ring1A-or Ring1B-null cells proliferate and self-renewal normally (82, 106) . While a single Ring1A depletion does not have a major impact on gene regulation, Ring1B is required to maintain gene repression of lineage-specific genes (78, 82) . In contrast to PRC2-null ESCs, complete impairment of all of the PRC1 complexes (in Ring1A/B double knock-out ESCs) strongly affects selfrenewal (107) , suggesting that the PRC2 and PRC1 complexes are not completely functionally redundant. Depleting Cbx7, RYBP, or Fbxl10 in ESCs does not compromise self-renewal of the E14Tg2a ESC strain, but depleting RYBP in TT2 ESCs decreases their proliferation (76, 77, 87, 91) .
Cbx7 is dispensable for ESC proliferation, although it is required to maintain gene repression of a large amount of PRC1 target genes. The aberrant upregulation of lineage-specific genes results in defects during differentiation of the ESCs into embryoid bodies (EBs), and more specifically, towards the neuroectoderm lineage (87, 88) . While Cbx7 is strongly downregulated during differentiation, Cbx2/4/8 are assembled into new cPRC1 complexes during EB differentiation. Interestingly, depletion of Cbx2 and Cbx4 resulted in lineagespecific phenotypes, indicating not only that Cbx proteins have non-overlapping functions in pluripotent and differentiating ESCs but also that the expression of Cbx2 and Cbx4 is important to drive the newly assembled cPRC1 complexes to specific and de novo loci during differentiation (87, 88) .
RYBP-null or knock-down ESCs also deregulate PRC1 target genes, and unlike Cbx7, RYBP is necessary during mesoderm differentiation (74, 76, 91) . RYBP is not functionally restricted to the ncPRC1 complex but is probably present in other chromatin-associated complexes; therefore, the precise contribution of RYBP in PRC1-mediated phenotypes is unclear. Although Fbxl10 depletion strongly impairs Ring1B activity and reduces global levels of H2AK119ub, changes in gene expression are very subtle (77, 89) . The lack of gene activation is probably due to the persistent binding of Cbx7 and PRC2 in cells depleted for 
PRC2.
Mutant mice for core PRC2 components display embryonic lethality at different developmental stages: Ezh2-null mice are embryonic lethal at day E8.5, Eed null mice, at E9.5, and Suz12 mice, between days E8.5 and E10.5 (69).
Eed, Suz12, or Ezh2 mutant ESCs self-renew and proliferate normally, but have a strongly compromised differentiation capacity (108) (109) (110) (111) (112) (113) . Surprisingly, the precise contribution of each of the PRC2 subunits during ESC lineage specification is still poorly understood. It has been shown that Eed null ESCs lose their cellular identity and are not able differentiate towards any specific cell lineage, yet another report indicates that Eed -/-ESCs are capable of developing teratomas that contain all three cell lineages but also have an overrepresentation of ectoderm and mesoderm tissues (114) . Suz12 mutant ESCs display defects during neuroectodermal and EB differentiation, and ESCs lacking Ezh2 fail to differentiate towards the mesoendoderm lineage (115) .
Regarding the PRC2-associated proteins in ESCs, Jarid2 is also essential during embryogenesis (116) . While Jarid2 and C17orf96 are also dispensable for ESC self-renewal, Mtf2-depleted ESCs self-renew faster (101) , and Phf19-depleted cells display a certain degree of spontaneous differentiation (100). Jarid2, Mtf2, and Phf19 are essential regulators of ESC differentiation, although they are rapidly downregulated during differentiation (93, 95, 96, 100, 102, 117) .
Why do genetic mutations of different PRC2 core components result in different phenotypes during ESC differentiation? A possible explanation is that the protein stability and function of the other PRC2 subunits differentially change when only one is depleted; for instance, ESCs lacking Eed have reduced levels of Ezh2 and normal Suz12 levels (114, 115) . In contrast, Ezh2 knock-out ESCs have normal Eed and Suz12 protein levels, and Ezh1 functionally compensates for the lack of Ezh2 (115), while Suz12 knock-out ESCs are impaired in Ezh2 stability and Ezh2-mediated enzymatic activity (109) . Furthermore, Ezh2 has been recently shown to have PRC2-independent functions in cancer (70) . Although it seems clear that Eed, Suz12, and Ezh2 are only associated to the PRC2 complex in pluripotent ESCs, it remains unclear whether they exhibit PRC2-independent functions during ESC differentiation, or whether other co-factors expressed during differentiation are assembled into new PRC2 complexes that in turn might have specific biological functions. Therefore, identifying further PRC2 subunits that associate during ESC differentiation will shed light on the biological function of PRC2 during differentiation.
Set1A/B and MLL complexes in ESCs.
In mammals, the Set1A/B and MLL family of complexes (MLL1-4) are responsible for methylation of the lysine 4 at the histone H3 (67, 118, 119) .
These can be further classified depending on the methyltransferase enzyme they contain as well as on their specific and common co-factors (Fig. 2 and Fig. 4C ).
In ESCs, lineage-specific genes marked by H3K4me3 and H3K27me3 are defined as bivalent genes, which, despite the presence of H3K4me3, are expressed only at low levels (80, 120) . Upon differentiation stimuli, bivalent genes become Wdr5 and Ash2l are subunits present in all Set1A/B and MLL complexes (Fig. 2) .
As their expression is rapidly downregulated upon ESC differentiation, they might exert specific functions that maintain the ESC state. Interestingly, WDR5 targets and directly controls the expression of several pluripotency genes, and its depletion results in loss of ESC self-renewal (124) . While Mll2 depletion does not alter global H3K4me3 levels, Wdr5 knock-down strongly reduces global H3K4me3 levels and upregulates H3K4me1/2 levels. Wdr5 also interacts with Oct4 (124) and has been found in pull-down experiments using Ring1B as bait (125) ESCs self-renewal normally and can give rise to teratomas, yet EBs derived from Utx mutant ESCs retain high levels of Oct4 and Nanog and do not properly differentiate (131) . Surprisingly, upon RA-induced differentiation, the H3K27me3 levels in Utx null cell are higher than those in wild-type differentiating cells, indicating that active H3K27me3 demethylation occurs in the absence of Utx during RA-mediated differentiation. Moreover, at the HOXB cluster, H3K4me3 levels are increased in cells lacking Utx (131) , suggesting a MLL complex-independent function of Utx. In male ESCs, Utx is also not required for self-renewal and proliferation, but it is required for mesoderm and ectoderm differentiation. Interestingly, the contribution of Utx in ESC differentiation appears to be independent of its enzymatic activity (132, 133) . 
Concluding Remarks
While much work remains to be done, it is clear that the roles of epigenetic factors and the fate regulation of ESCs are strongly connected, maybe even more so than previously believed. In the past years, our understanding of the mechanisms that govern the proliferation of pluripotent stem cells and of the processes that lead to lineage choice has dramatically increased. This knowledge will significantly contribute to identifying more effective conditions for reprogramming differentiated cells into pluripotent conditions, which will facilitate the development of specialized stem cell-based therapies. Moreover, given the multiple similarities between undifferentiated ESCs with initiating cancer cells, the identification of novel drugs targeting chromatin modifiers, together with the optimization of those already available, will surely improve cancer therapies. 
